A METHOD FOR PREDICTING RECURRENCE OF OVARIAN ENDOMETRIOD CYST

EA054713B1Active Publication Date: 2026-09-29PAVLOVSKAYA MARIYA ANDREEVNA +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EA202490040
Authority / Receiving Office
EA · EA
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-12-14
Publication Date
2026-09-29
Estimated Expiration
2043-12-14
Patent Text Reader

Abstract

The invention relates to medicine, in particular to gynecology. The essence of the invention is that after surgical treatment - ovarian resection or cystectomy - an immunohistochemical study of the tissue of an endometrioid ovarian cyst is carried out, while determining the expression levels of matrix metalloproteinase-9 (MMP-9), cyclins B1 and D1. If the value of MMP-9 is more than 5 points, cyclin B1 is more than 3 points and D1 is more than 4 points, a relapse of an endometrioid ovarian cyst is predicted. The method has a high prognostic significance, which allows for timely implementation of appropriate treatment and preventive measures to prevent reproductive dysfunction in women.
Need to check novelty before this filing date? Find Prior Art

Claims

A method for predicting the risk of recurrence of an endometrioid ovarian cyst, including an immunohistochemical study of the tissue of an endometrioid ovarian cyst taken after surgery to remove the cyst, characterized in that the levels of expression of matrix metalloproteinase-9 (MMP-9), cyclins B1 and D1 are determined in the tissue of the endometrioid ovarian cyst by an immunohistochemical method, where the results of the immunohistochemical reactions are assessed in points from 1 to 6 by a semi-quantitative method based on the percentage of stained cells: 0 points - no stained cells, 1 point - 5-10%, 2 points - 10-20%, 4 points - 20-40%, 6 points - more than 40% positive cells, and with an MMP-9 value of more than 5 points, cyclin B1 more than 3 points and cyclin D1 more than 4 points, a relapse is predicted.